|
시장보고서
상품코드
1937604
여성 건강 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Women Health Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
여성 건강 치료제 시장 규모는 2025년 533억 1,000만 달러에서 2034년에는 801억 2,000만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 4.63%로 성장할 전망입니다.
여성 건강 문제에 대한 인식이 높아지고 표적 치료제에 대한 수요가 증가함에 따라 여성 건강 치료제 시장은 큰 폭의 성장이 예상됩니다. 생식 건강, 갱년기, 만성질환 등 여성들이 평생 동안 직면하게 되는 건강 문제에 대응하기 위해 효과적인 치료법의 필요성이 급증하고 있습니다. 의료 서비스 제공자들이 여성의 다양한 생애주기에 따른 다양한 요구를 충족시키기 위해 호르몬 요법, 비호르몬 치료, 생활습관 중재 등 혁신적인 치료법이 증가하고 있습니다.
의약품 개발 및 약물전달의 혁신이 여성 건강 치료제 시장의 향후 전망을 형성하고 있습니다. 개인의 유전적, 호르몬적 프로파일을 고려한 맞춤형 의료 접근법의 등장으로 자궁내막증, 다낭성난소증후군(PCOS), 갱년기 증상 등의 질환에 대한 치료 효과가 높아지고 있습니다. 또한, 원격의료와 디지털 건강 솔루션의 발전으로 의료 접근성이 향상되어 여성들이 자신의 건강을 보다 효과적으로 관리할 수 있게 되었습니다. 여성 건강과 관련된 복잡한 메커니즘이 조사를 통해 계속 밝혀지고 있는 가운데, 특정 질환을 대상으로 하고 전반적인 건강 상태를 개선하는 새로운 치료법이 시장에 출시될 가능성이 높습니다.
또한, 제약회사와 의료 기관이 여성 건강 수요에 대한 대응의 중요성을 인식함에 따라 연구개발에 대한 투자 증가는 여성 건강 치료제 시장에 긍정적인 영향을 미칠 것으로 보입니다. 의료 제공자, 연구자, 지원 단체 간의 협력 체계는 인지도 향상과 효과적인 치료 접근성을 확보하는 데 필수적인 요소입니다. 변화하는 환경 속에서 규제 당국은 여성의 고유한 요구에 부합하는 혁신적인 치료법 개발을 지원하고, 새로운 솔루션에 대한 신속한 접근을 촉진할 것으로 기대됩니다. 점차 여성 건강 치료를 종합적인 건강 관리 전략에 통합하는 데 초점을 맞추고, 여성 건강 상태를 개선하는 데 있어 교육, 예방 및 지속적인 지원의 중요성을 강조할 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 여성 건강 치료제 시장 : 용도별
제5장 세계의 여성 건강 치료제 시장 : 연령별
제6장 세계의 여성 건강 치료제 시장 : 약물별
제7장 세계의 여성 건강 치료제 시장 : 유통 채널별
제8장 세계의 여성 건강 치료제 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM 26.03.12The Women Health Therapeutics Market size is expected to reach USD 80.12 Billion in 2034 from USD 53.31 Billion (2025) growing at a CAGR of 4.63% during 2026-2034.
The women health therapeutics market is poised for substantial growth, driven by the increasing awareness of women's health issues and the rising demand for targeted therapies. As women face unique health challenges throughout their lives, including reproductive health, menopause, and chronic conditions, the need for effective treatment options is surging. The market is witnessing a rise in innovative therapeutics, including hormonal therapies, non-hormonal treatments, and lifestyle interventions, as healthcare providers seek to address the diverse needs of women across different life stages.
Innovations in drug development and delivery methods are shaping the future of the women health therapeutics market. The emergence of personalized medicine approaches, which consider individual genetic and hormonal profiles, is enhancing the effectiveness of treatments for conditions such as endometriosis, polycystic ovary syndrome (PCOS), and menopausal symptoms. Additionally, advancements in telehealth and digital health solutions are improving access to care and enabling women to manage their health more effectively. As research continues to uncover the complexities of women's health, the market is likely to witness the introduction of novel therapies that target specific conditions and improve overall well-being.
Moreover, the women health therapeutics market will benefit from increased investment in research and development, as pharmaceutical companies and healthcare organizations recognize the importance of addressing women's health needs. Collaborative efforts between healthcare providers, researchers, and advocacy groups will be essential in promoting awareness and ensuring access to effective treatments. As the landscape evolves, regulatory bodies are expected to support the development of innovative therapies that align with the unique needs of women, facilitating faster access to new solutions. The focus will increasingly shift towards integrating women's health therapeutics into comprehensive healthcare strategies, emphasizing the importance of education, prevention, and ongoing support in improving health outcomes for women.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Application
- Hormonal Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Polycystic Ovary Syndrome (PCOS)
By Age
- 50 Years & Above
- Others
By Drug
- ACTONEL
- YAZ, Yasmin, Yasminelle
- FORTEO
- Minastrin 24 Fe
- Mirena
- NuvaRing
- ORTHO TRI-CY LO
- Premarin
- Prolia
- Reclast/Aclasta
- XGEVA
- Zometa
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
COMPANIES PROFILED
- Bayer AG, Pfizer Inc, Cipla Inc, Orchid Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical, F HoffmannLa Roche Ltd, AbbVie, Axena Health
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Application
- 4.2. Hormonal Infertility Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Postmenopausal Osteoporosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Endometriosis & Uterine Fibroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.6. Menopause Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.7. Polycystic Ovary Syndrome (PCOS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET: BY AGE 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Age
- 5.2. 50 Years & Above Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET: BY DRUG 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Drug
- 6.2. ACTONEL Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. YAZ, Yasmin, Yasminelle Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. FORTEO Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Minastrin 24 Fe Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.6. Mirena Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.7. NuvaRing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.8. ORTHO TRI-CY LO Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.9. Premarin Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.10. Prolia Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.11. Reclast/Aclasta Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.12. XGEVA Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.13. Zometa Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.14. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Distribution Channel
- 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Application
- 8.2.2 By Age
- 8.2.3 By Drug
- 8.2.4 By Distribution Channel
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Application
- 8.3.2 By Age
- 8.3.3 By Drug
- 8.3.4 By Distribution Channel
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Application
- 8.4.2 By Age
- 8.4.3 By Drug
- 8.4.4 By Distribution Channel
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Application
- 8.5.2 By Age
- 8.5.3 By Drug
- 8.5.4 By Distribution Channel
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Application
- 8.6.2 By Age
- 8.6.3 By Drug
- 8.6.4 By Distribution Channel
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL WOMEN HEALTH THERAPEUTICS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Bayer AG
- 10.2.2 Pfizer Inc
- 10.2.3 Cipla Inc
- 10.2.4 Orchid Pharma
- 10.2.5 Sun Pharmaceutical Industries Ltd
- 10.2.6 Teva Pharmaceutical
- 10.2.7 F. Hoffmann-La Roche Ltd
- 10.2.8 AbbVie
- 10.2.9 Axena Health
